Pharma Mar, S.A.

BME:PHM Stock Report

Market Cap: €1.6b

Pharma Mar Management

Management criteria checks 1/4

Pharma Mar's CEO is Jose Fernandez Sousa-Faro, appointed in Jan 1986, has a tenure of 39.08 years. directly owns 6.4% of the company’s shares, worth €103.23M. The average tenure of the management team and the board of directors is 10.1 years and 2.7 years respectively.

Key information

Jose Fernandez Sousa-Faro

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure39.1yrs
CEO ownership6.4%
Management average tenure10.1yrs
Board average tenure2.7yrs

Recent management updates

Recent updates

Pharma Mar, S.A.'s (BME:PHM) Price Is Right But Growth Is Lacking After Shares Rocket 55%

Oct 16
Pharma Mar, S.A.'s (BME:PHM) Price Is Right But Growth Is Lacking After Shares Rocket 55%

Pharma Mar, S.A.'s (BME:PHM) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Jul 28
Pharma Mar, S.A.'s (BME:PHM) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65

Jun 01
Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65

Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry

May 28
Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry

Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 03
Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden

Jan 25
Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden

Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate

Apr 28
Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate

We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability

Mar 08
We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability

Analyst Forecasts Just Became More Bearish On Pharma Mar, S.A. (BME:PHM)

Mar 05
Analyst Forecasts Just Became More Bearish On Pharma Mar, S.A. (BME:PHM)

Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

Feb 09
Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease

Oct 27
We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease

An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued

Sep 27
An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued

Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?

Jul 15
Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?

Growth Investors: Industry Analysts Just Upgraded Their Pharma Mar, S.A. (BME:PHM) Revenue Forecasts By 24%

May 04
Growth Investors: Industry Analysts Just Upgraded Their Pharma Mar, S.A. (BME:PHM) Revenue Forecasts By 24%

Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet

Apr 11
Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet

There Is A Reason Pharma Mar, S.A.'s (BME:PHM) Price Is Undemanding

Mar 16
There Is A Reason Pharma Mar, S.A.'s (BME:PHM) Price Is Undemanding

Is Pharma Mar (BME:PHM) Using Too Much Debt?

Jan 09
Is Pharma Mar (BME:PHM) Using Too Much Debt?

Pharma Mar (BME:PHM) Seems To Use Debt Quite Sensibly

Sep 08
Pharma Mar (BME:PHM) Seems To Use Debt Quite Sensibly

News Flash: Analysts Just Made A Meaningful Upgrade To Their Pharma Mar, S.A. (BME:PHM) Forecasts

Aug 03
News Flash: Analysts Just Made A Meaningful Upgrade To Their Pharma Mar, S.A. (BME:PHM) Forecasts

Here's Why I Think Pharma Mar (BME:PHM) Is An Interesting Stock

May 31
Here's Why I Think Pharma Mar (BME:PHM) Is An Interesting Stock

Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

May 10
Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

Is Pharma Mar, S.A. (BME:PHM) Expensive For A Reason? A Look At Its Intrinsic Value

Apr 08
Is Pharma Mar, S.A. (BME:PHM) Expensive For A Reason? A Look At Its Intrinsic Value

Announcing: Pharma Mar (BME:PHM) Stock Increased An Energizing 231% In The Last Five Years

Jan 14
Announcing: Pharma Mar (BME:PHM) Stock Increased An Energizing 231% In The Last Five Years

Is Pharma Mar (BME:PHM) A Risky Investment?

Nov 19
Is Pharma Mar (BME:PHM) A Risky Investment?

CEO

Jose Fernandez Sousa-Faro

39.1yrs

Tenure

€294,000

Compensation

Mr. José María Fernández Sousa-Faro, Ph D., founded Pharma Mar, S.A.U. in 1986. He Founded Noscira, S.A., in 2000.He serves as the Chief Executive Officer and President of Pharma Mar, S.A.U. He serves as...

Leadership Team

NamePositionTenureCompensationOwnership
Jose Fernandez Sousa-Faro
Founder39.1yrs€294.00k6.4%
€ 103.2m
Pedro Fernandez Puentes
Executive Vice-Chairmanno data€124.00k0.00057%
€ 9.2k
Juan Carretero
Founderno datano datano data
María de Francia Caballero
Chief Financial Officer25.1yrsno datano data
José Moreno Martinez-Losa
Head of Capital Markets & Investor Relations10.1yrsno datano data
Juan Pulido
General Counsel & Secretary of the Board of Directors5.4yrsno datano data
Sandra Sanchez
Global Compliance Head4.8yrsno datano data
Lara Vadillo
Communication Directorno datano datano data
Belén Veramendi
Director of Corporate Development3.1yrsno datano data
Luis Cuenca
Director of Human Resources & IT21.6yrsno datano data
Pascal Besman
Chief Operating Officer of Pharmar U.S.no datano datano data
Maria Arce
Global Head of Regulatory Affairsno datano datano data

10.1yrs

Average Tenure

Experienced Management: PHM's management team is seasoned and experienced (10.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jose Fernandez Sousa-Faro
Founderno data€294.00k6.4%
€ 103.2m
Pedro Fernandez Puentes
Executive Vice-Chairmanno data€124.00k0.00057%
€ 9.2k
Eduardo Serra Rexach
Independent Other External Director4.1yrs€35.00kno data
M. Solchaga Catalan
Independent Other External Directorno data€35.00kno data
Montserrat Andrade Detrell
Proprietary Directorno data€34.00k5.49%
€ 88.5m
Blanca Hernandez Rodriguez
Independent Director6.1yrsno datano data
Maria Sandra Mera
Representative Proprietary Director4.2yrsno datano data
Rosa Maria Alonso
Independent Director2.7yrsno datano data
Mariano Rodriguez
Independent Coordinating Director2.7yrsno datano data
Emiliano Aller
Independent Director2.7yrsno datano data
Fernando Santos
Independent Other External Directorno datano datano data
Soledad Miranda
Independent Director1.8yrsno datano data

2.7yrs

Average Tenure

Experienced Board: PHM's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/03 01:56
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pharma Mar, S.A. is covered by 11 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Guilherme SampaioBanco BPI, S.A.
Patricia CifuentesBestinver Sociedad De Valores, S.A
Keay NakaeChardan Capital Markets, LLC